Oct 24, 2024 / 05:00PM GMT
Christianne Ibanez - Genomma Lab Internacional SAB de CV - Head of Investor Relations
Are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today and the company undertakes no obligation to update them as a result of new information or future events. Let me now turn the call over to Marco.
Juan Marco Sparvieri - Genomma Lab Internacional SAB de CV - Chief Executive Officer
Good morning, everyone, and thank you, Chris. I am thrilled to share our strong Q 3 2024 results.
This quarter, we have seen substantial progress across all key metrics surpassing last year's results. Previous periods and our internal targets sales increased by 15.9% driven by excellent performance in major markets such as Mexico, Brazil, Argentina and the US gross margin improved by 184 basis points reaching 64.3%.
EBITDA expanded by 245 basis points reaching [23.7%] fueled by our productivity initiatives and manufacturing efficiencies.
Net income surged by 78.1% and earnings per share
Q3 2024 Genomma Lab Internacional SAB de CV Earnings Call Transcript
Oct 24, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers